Skip to main content
Skip to content
Case File
kaggle-ho-024658House Oversight

Ackrell Capital Cannabis Investment Report – Technical Overview of CBDA and Decarboxylation (Dec 2017)

Ackrell Capital Cannabis Investment Report – Technical Overview of CBDA and Decarboxylation (Dec 2017) The passage is a purely scientific/financial overview of cannabinoid chemistry and investment context. It contains no mention of political figures, government agencies, financial flows tied to powerful actors, or allegations of misconduct. Consequently, it offers no actionable investigative lead. Key insights: Describes CBDA as a non‑psychoactive precursor to CBD with potential medical benefits.; Notes recent cultivation of cannabis strains with high CBDA levels comparable to THC.; Explains decarboxylation process converting CBGA into various cannabinoids.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024658
Pages
1
Persons
0
Integrity
No Hash Available

Summary

Ackrell Capital Cannabis Investment Report – Technical Overview of CBDA and Decarboxylation (Dec 2017) The passage is a purely scientific/financial overview of cannabinoid chemistry and investment context. It contains no mention of political figures, government agencies, financial flows tied to powerful actors, or allegations of misconduct. Consequently, it offers no actionable investigative lead. Key insights: Describes CBDA as a non‑psychoactive precursor to CBD with potential medical benefits.; Notes recent cultivation of cannabis strains with high CBDA levels comparable to THC.; Explains decarboxylation process converting CBGA into various cannabinoids.

Tags

kagglehouse-oversightcannabiscbdainvestment-reportchemical-analysisdrug-policy

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
OY CKRELL APITAL Cannabis Investment Report | December 2017 CBDA (Cannabidiolic Add: CBDA, the precursor to CBD, is nonpsychoactive and is believed to have several medicinal benefits—anticancer, antiemetic and anti-inflammatory—as well as therapeu- tic applications. Generally, CBDA is present in the cannabis plant in low levels, although recently some strains have been grown with CBDA levels comparable to typical THC levels. Like THCA, CBDA decarboxylates into other compounds when heated. (An explanation of decarboxylation follows.) Cannabinoid Composition Levels As a general rule, THC and CBD are the most prevalent cannabinoids found in many strains of the cannabis plant, with other cannabinoids appearing in relatively minuscule amounts. (One exception to this rule is the low-THC strains grown to produce industrial hemp.) THC-dominant strains histor- ically have been the most popular with cannabis consumers, but CBD-dominant strains and strains with high levels of other cannabinoids are believed to have medicinal benefits and hold promise for therapeutic applications. Cannabinoid Creation: Decarboxylation All cannabinoids present in cannabis begin as cannabigerolic acid, or CBGA. CBGA is ultimately transformed into various other cannabinoids through decarboxylation, a process by which a com- pound’s chemical structure changes due to light, heat, alkaline conditions or other chemical forces. The two main catalysts for decarboxylation of CBGA and other cannabinoids are heat and time (the aging process). The following chart depicts the process of cannabinoid decarboxylation. Cannabinoid Decarboxylation Process HEATED CBNA A8 - THC CBN CBL Source: Elemental Wellness 22 © 2017 Ackrell Capital, LLC | Member FINRA/SIPC

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.